What is Sagimet Biosciences Inc. Series A Common Stock (SGMT) stock price today?

Sagimet Biosciences Inc. Series A Common Stock (SGMT) currently trades at $7.71 per share. The stock has a market capitalization of $476.11M and a P/E ratio of —x.

Is SGMT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Sagimet Biosciences Inc. Series A Common Stock has a Smart Value Score of 21/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is —.

Is Sagimet Biosciences Inc. Series A Common Stock financially healthy?

Sagimet Biosciences Inc. Series A Common Stock's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of — places it in the —.

SGMT

Sagimet Biosciences Inc. Series A Common Stock

NASDAQ: SGMT · HEALTHCARE · BIOTECHNOLOGY

$7.71

+0.92% today

Updated 2026-05-08

Market cap

$476.11M

P/E ratio

—

P/S ratio

52.50x

EPS (TTM)

$-1.59

Dividend yield

—

52W range

$3 – $11

Volume

1.6M

Market cap

$476.11M

P/E ratio

—

P/S ratio

52.50x

EPS (TTM)

$-1.59

Dividend yield

—

52W range

$3 – $11

Volume

1.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →194 stocks currently score above 75

Price targets

Analyst target

$28.50

+269.65%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-11.83M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$2.00M	$0.00	$0.00	$0.00
Net income	$-30.50M	$-27.88M	$-45.57M	$-51.04M	$-9.57M
EPS	—	—	—	—	$-1.59
Free cash flow	$-24.49M	$-23.77M	$-42.44M	$-45.65M	$-11.83M
Profit margin	—	-1,393.80%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SGMT	$476.11M	21	4.3	3.0	5.0	7.3	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Sagimet Biosciences Inc. Series A Common Stock trades at $7.71. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Sagimet Biosciences Inc. Series A Common Stock's stock price?

Sagimet Biosciences Inc. Series A Common Stock (SGMT) trades at $7.71.

Is Sagimet Biosciences Inc. Series A Common Stock overvalued?

Smart Value Score 21/100 (Grade F, Strong Sell).

What is the price target of Sagimet Biosciences Inc. Series A Common Stock (SGMT)?

The analyst target price is $28.50, representing +269.6% upside from the current price of $7.71.

Piotroski F-Score?

3/9 — weak financial health.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio52.50x

ROE-38.20%

Beta3.64

50D MA$5.95

200D MA$6.75

Shares out0.06B

Float0.03B

Short ratio—

Avg volume1.6M

Performance

1 week-2.41%

1 month+45.47%

3 months+41.47%

YTD+30.24%

1 year—

3 years—

5 years—

Compare

SGMT vs LLY →SGMT vs JNJ →SGMT vs ABBV →Stock screener →